Clinical Trials Directory

Trials / Completed

CompletedNCT03721380

Efficacy of Drug and Risk Behavior Counseling Intervention Among Injecting Drug Users at Opioid Substitution Treatment

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
118 (actual)
Sponsor
National Taiwan University · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Accepted

Summary

Behavior drug and risk reduction counseling (BDRC), a structured, non-intense, cognitive-behavioral approach intervention designed to increase methadone maintenance treatment retention and reduce drug use and related risk behaviors among IDUs.

Detailed description

Techniques of the Cognitive Behavior Therapy combined with drug dependence psychoeducation was developed by research team. BDRC consists of 12 sessions, including an initial session, 3 drug education sesssions, psychosocial counseling and behavioral skills. This initial session is designed to introduce the counselor, review the purpose and expectations of counseling, review the rules of confidentiality, agree on attendance times and rescheduling rules, and to begin to collect information from the participant on their drug use and risk behaviors. Behavioral contracting is a key component to this counseling approach. Drug education focuses on how heroin may influence patients' cognitive function and their HIV/HCV risk behaviors. Counseling and behavior skills trained patients to reflect their thoughts and learned new life skills in order to delay or abstrain from heroin use.

Conditions

Interventions

TypeNameDescription
BEHAVIORALTreatment as usualPatients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs. During MMT treatment, the participant receives monthly random urine testing for opiate use and HIV testing as needed. Monthly meetings between the patient and physician are expected to occur however, there is no structure to these sessions and content is considered to be quite variable.

Timeline

Start date
2012-05-14
Primary completion
2014-07-31
Completion
2015-07-31
First posted
2018-10-26
Last updated
2018-10-26

Source: ClinicalTrials.gov record NCT03721380. Inclusion in this directory is not an endorsement.